Licensing deals involving drugs for central nervous system conditions were worth more in 2016 than previous years, although there are fewer agreements being signed in this disease space. One of the most lucrative CNS pacts since 2012 was AbbVie Inc. and Google-funded start-up Calico Life Sciences LLC's arrangement for new treatments targeting Alzheimer's and other diseases related to aging.
According to new research from Datamonitor Healthcare, from 2012 through 2015 the total potential deal value for CNS therapies each...